Compare Chevron Corp (CVX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Sana Biotechnology Inc — how do they compare? Chevron Corp trades at $180.28 (market cap $361.99B), while Sana Biotechnology Inc trades at $3.54 (market cap $994.89M). The key difference: Chevron Corp is far larger — about 363.8× Sana Biotechnology Inc's market cap, and Chevron Corp pays a 3.92% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| CVX | SANA | |
|---|---|---|
Market Cap | $361.99B | $994.89M |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $5.92 |
52-Week Low | $146.72 | $2.68 |
Enterprise Value | $402.09B | $969.08M |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $182.21, up 3.29% on the day, with bullish technical signals from moving averages and ADX indicators. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.41 surpassing the $1.00 estimate. The company maintains strong operating cash flow of $33.94 billion in 2025 and announced a $13.8 billion investment in Argentina's Vaca Muerta shale project, signaling growth commitment.
The outlook remains positive with a consensus price target of $207.56, implying 13.9% upside. High oil prices and strategic expansions support growth, but declining profit margins and geopolitical tensions pose risks. Analyst sentiment is strongly bullish with 62% buy ratings, though investors should monitor debt levels, which rose to 12.35% of assets in 2025.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
